Drug Information

General Information
Drug ID
DR00120
Drug Name
Lapatinib
Synonyms
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; FMM; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (ERBB2 inhibitor); Lapatinib (INN); Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; Lapatinib, Tykerb, GW572016; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; Tycerb; Tykerb (TN)
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C29H26ClFN4O4S
Canonical SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChI
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChIKey
BCFGMOOMADDAQU-UHFFFAOYSA-N
CAS Number
CAS 388082-78-8
Pharmaceutical Properties Molecular Weight 581.1 Topological Polar Surface Area 115
Heavy Atom Count 40 Rotatable Bond Count 11
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 9
XLogP
5.1
PubChem CID
208908
PubChem SID
103177479 , 103854383 , 103905567 , 103905568 , 109692966 , 113442073 , 117695459 , 124360113 , 124893335 , 124893336 , 125345521 , 126592984 , 126621155 , 126649062 , 126666978 , 126667073 , 126731332 , 127325943 , 127325944 , 127325945 , 127494626 , 134338132 , 135128225 , 135685383 , 135685387 , 14911387 , 21317859 , 30413551 , 46393564 , 46506302 , 46507141 , 49742619 , 50070568 , 50071307 , 50100107 , 50112760 , 50644701 , 53788364 , 57399558 , 585695 , 7887520 , 8035064 , 85171071 , 85202079 , 91147938 , 92308826 , 92719029 , 93581028 , 9368726 , 96024798
ChEBI ID
ChEBI:49603
TTD Drug ID
D08CDI
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [3]
References
1 Lapatinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
3 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.